Cost Effectiveness of Strategies to Manage Atrial Fibrillation in Middle- and High-Income Countries: A Systematic Review

[1]  A. Millier,et al.  Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain , 2022, PloS one.

[2]  S. Staniszewska,et al.  Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations , 2022, PharmacoEconomics.

[3]  Ming Hu,et al.  Long-Term Cost-Effectiveness Comparison of Catheter Ablation and Antiarrhythmic Drugs in Atrial Fibrillation Treatment Using Discrete Event Simulation. , 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[4]  M. Jiang,et al.  Cost‐effectiveness of anticoagulants for preventing stroke in patients with non‐valvular atrial fibrillation in mainland China , 2021, Journal of clinical pharmacy and therapeutics.

[5]  P. Sritara,et al.  Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis , 2021, BMJ Evidence-Based Medicine.

[6]  I. V. Van Gelder,et al.  Update on management of atrial fibrillation in heart failure: a focus on ablation , 2021, Heart.

[7]  D. Frame,et al.  Cost‐effectiveness of catheter ablation versus medical therapy for the treatment of atrial fibrillation in the United Kingdom , 2021, Journal of cardiovascular electrophysiology.

[8]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[9]  P. Scuffham,et al.  Long-term cost-effectiveness of a disease management program for patients with atrial fibrillation compared to standard care – a multi-state survival model based on a randomized controlled trial , 2021, Journal of medical economics.

[10]  OUP accepted manuscript , 2021, European Heart Journal.

[11]  Sathish Kumar Jayapal,et al.  Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019 , 2020, Journal of the American College of Cardiology.

[12]  S. Straus,et al.  Cost-effectiveness of antithrombotic agents for atrial fibrillation in older adults at risk for falls: a mathematical modelling study. , 2020, CMAJ open.

[13]  P. Scuffham,et al.  Cost-effectiveness of combined catheter ablation and left atrial appendage closure for symptomatic atrial fibrillation in patients with high stroke and bleeding risk. , 2020, American heart journal.

[14]  E. Walter,et al.  Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients , 2020, Expert review of pharmacoeconomics & outcomes research.

[15]  R. Krittayaphong,et al.  Cost-Effectiveness Analysis of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Thai Patients With Non-Valvular Atrial Fibrillation. , 2020, Heart, lung & circulation.

[16]  B. Joung,et al.  Cost-Effectiveness of Rate- and Rhythm-Control Drugs for Treating Atrial Fibrillation in Korea , 2019, Yonsei medical journal.

[17]  R. Tieleman,et al.  Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings , 2019, PloS one.

[18]  H. Yin,et al.  A Long-Term Cost-Effectiveness Analysis Comparing Radiofrequency Catheter Ablation with Antiarrhythmic Drugs in Treatment of Chinese Patients with Atrial Fibrillation , 2019, American Journal of Cardiovascular Drugs.

[19]  H. Elewa,et al.  Cost-effectiveness Evaluations Among the Direct Oral Anticoagulants for the Prevention and Treatment of Venous Thromboembolism: Systematic Review , 2019, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[20]  F. Silva,et al.  Cost-effectiveness of new oral anticoagulants and warfarin in atrial fibrillation from adverse events perspective , 2019, Revista Colombiana de Cardiología.

[21]  L. Aminde,et al.  Atrial fibrillation among adults with heart failure in sub-Saharan Africa — prevalence, incidence and all-cause mortality: a systematic review and meta-analysis protocol , 2019, BMJ Open.

[22]  J. Xuan,et al.  Radiofrequency Catheter Ablation Versus Cryoballoon Ablation in the Treatment of Paroxysmal Atrial Fibrillation: A Cost-effectiveness Analysis in China. , 2019, Clinical therapeutics.

[23]  K. Sawanyawisuth,et al.  Cost-Effectiveness Analysis of Direct-Acting Oral Anticoagulants for Stroke Prevention in Thai Patients with Non-Valvular Atrial Fibrillation and a High Risk of Bleeding , 2018, PharmacoEconomics.

[24]  Kenneth J. Smith,et al.  Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding , 2018, American Journal of Cardiovascular Drugs.

[25]  O. Franco,et al.  Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study , 2017, Systematic Reviews.

[26]  Christopher X. Wong,et al.  Cost-Effectiveness and Clinical Effectiveness of the Risk Factor Management Clinic in Atrial Fibrillation: The CENT Study. , 2017, JACC. Clinical electrophysiology.

[27]  S. Ikeda,et al.  A cost-utility analysis for catheter ablation of atrial fibrillation in combination with warfarin and dabigatran based on the CHADS2 score in Japan. , 2017, Journal of cardiology.

[28]  Chieh-Yu Liu,et al.  Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan , 2017, Clinical Drug Investigation.

[29]  J. Saw,et al.  Cost-Effectiveness of Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Patients With Contraindications to Anticoagulation. , 2016, The Canadian journal of cardiology.

[30]  A. Verma,et al.  Cost-effectiveness of Catheter Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Atrial Fibrillation: A Canadian Perspective , 2016 .

[31]  W. Lim,et al.  Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation. , 2016, International journal of cardiology.

[32]  B. Yan,et al.  Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation , 2016, BMC Cardiovascular Disorders.

[33]  V. Roldán,et al.  A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation , 2016, Cardiology and Therapy.

[34]  M. Pirmohamed,et al.  Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden , 2016, The Pharmacogenomics Journal.

[35]  K. Athanasakis,et al.  Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting , 2015, Clinical Drug Investigation.

[36]  J. You.  Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. , 2015, Pharmacogenomics.

[37]  J. Ferreira,et al.  Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation. , 2015, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[38]  Mitja Kos,et al.  Cost Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation Depending on the Quality of Warfarin Anticoagulation Control , 2015, PharmacoEconomics.

[39]  V. Thijs,et al.  Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin , 2015, Clinical Drug Investigation.

[40]  M. Tubaro,et al.  Cost‑effectiveness analysis of apixaban versus other NOACs for the prevention of stroke in Italian atrial fibrillation patients , 2014 .

[41]  S. Sorensen,et al.  Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting. , 2014, Clinical therapeutics.

[42]  A. de Boer,et al.  Cost Effectiveness of New Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in Two Different European Healthcare Settings , 2014, American Journal of Cardiovascular Drugs.

[43]  H. Ng,et al.  Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation , 2014, Cardiovascular Drugs and Therapy.

[44]  I. Durand-zaleski,et al.  Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin , 2014, Journal of medical economics.

[45]  M. Reynolds,et al.  Cost-effectiveness of cryoballoon ablation for the management of paroxysmal atrial fibrillation. , 2014, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[46]  K. Civello,et al.  Cost-effectiveness of the convergent procedure and catheter ablation for non-paroxysmal atrial fibrillation , 2014, Journal of medical economics.

[47]  David M Herrington,et al.  Atrial fibrillation and the risk of myocardial infarction. , 2015, JAMA internal medicine.

[48]  Ben He,et al.  Cost–Effectiveness of Different Strategies for Stroke Prevention in Patients with Atrial Fibrillation in a Health Resource-Limited Setting , 2014, Cardiovascular Drugs and Therapy.

[49]  A. Braga,et al.  Stroke Prevention in Non-Valvular Atrial Fibrillation: Systematic Review of Cost-Effectiveness Studies , 2013 .

[50]  M. Neyt,et al.  The cost-utility of catheter ablation of atrial fibrillation: a systematic review and critical appraisal of economic evaluations , 2013, BMC Cardiovascular Disorders.

[51]  Simon Stewart,et al.  Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. , 2013, International journal of cardiology.

[52]  D. Coyle,et al.  Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[53]  W. Baker,et al.  Cost-effectiveness of newer anticoagulants for stroke prevention in atrial fibrillation: A systematic literature review , 2013 .

[54]  Silvana Quaglini,et al.  Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis , 2013, Clinical Drug Investigation.

[55]  A. Camm,et al.  Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, European heart journal.

[56]  H. Crijns,et al.  Rate control is more cost-effective than rhythm control for patients with persistent atrial fibrillation--results from the RAte Control versus Electrical cardioversion (RACE) study. , 2004, European heart journal.